(Q73226848)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11092643%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

title

Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11092643%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference

coronary artery disease

1 reference

B D Horne

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11092643%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

J B Muhlestein

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11092643%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

J F Carlquist

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11092643%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

T L Bair

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11092643%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

T E Madsen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11092643%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

N I Hart

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11092643%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

J L Anderson

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11092643%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

language of work or name

English

0 references

publication date

1 November 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11092643%20AND%20SRC:MED&resulttype=core&format=json

Journal of the American College of Cardiology

2 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11092643%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

volume

36

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11092643%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11092643%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

page(s)

1774-1780

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11092643%20AND%20SRC:MED&resulttype=core&format=json

Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group

2 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900950-5

7 January 2021

The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholester

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900950-5

7 January 2021

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900950-5

7 January 2021

C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900950-5

7 January 2021

Inflammation, atherosclerosis, and ischemic events -- exploring the hidden side of the moon.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900950-5

7 January 2021

Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900950-5

7 January 2021

Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900950-5

7 January 2021

C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900950-5

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900950-5

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900950-5

7 January 2021

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900950-5

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900950-5

7 January 2021

Statins do more than just lower cholesterol

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900950-5

7 January 2021

Antiatherothrombotic properties of statins: implications for cardiovascular event reduction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900950-5

7 January 2021

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900950-5

7 January 2021

Plasma homocysteine levels and mortality in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900950-5

7 January 2021

Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900950-5

7 January 2021

Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900950-5

7 January 2021

Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900950-5

7 January 2021

Inhibitor of proliferation of arterial smooth-muscle cells by fluvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900950-5

7 January 2021

Direct vascular effects of HMG-CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900950-5

7 January 2021

Simvastatin, a potent HMG-CoA reductase inhibitor, inhibits the proliferation of human and bovine endothelial cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900950-5

7 January 2021

Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900950-5

7 January 2021

Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900950-5

7 January 2021

Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900950-5

7 January 2021

Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900950-5

7 January 2021

Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900950-5

7 January 2021

The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900950-5

7 January 2021

Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900950-5

7 January 2021

Effect of statins on C-reactive protein in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900950-5

7 January 2021

Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900950-5

7 January 2021

10.1016/S0735-1097(00)00950-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11092643%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference